Serum levels of hyaluronic acid are associated with COPD severity and predict survival

Eleni Papakonstantinou; Ioannis Bonovolias; Michael Roth; Michael Tamm; Desiree Schumann; Florent Baty; Renaud Louis; Branislava Milenkovic; Wim Boersma; Bram Stieltjes; Konstantinos Kostikas; Francesco Blasi; Joachim G. Aerts; Gernot G. U. Rohde; Alicia Lacoma; Antoni Torres; Tobias Welte; Daiana Stolz

doi:10.1183/13993003.01183-2018

Serum levels of hyaluronic acid are associated with COPD severity and predict survival

Eleni Papakonstantinou, Ioannis Bonovolias, Michael Roth, Michael Tamm, Desiree Schumann, Florent Baty, Renaud Louis, Branislava Milenkovic, Wim Boersma, Bram Stieltjes, Konstantinos Kostikas, Francesco Blasi, Joachim G. Aerts, Gernot G. U. Rohde, Alicia Lacoma, Antoni Torres, Tobias Welte, Daiana Stolz^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Hyaluronic acid (HA) and its degradation products play an important role in lung pathophysiology and airway remodelling in chronic obstructive pulmonary disease (COPD).

We investigated if HA and its degrading enzyme hyaluronidase (HYAL)-1 are associated with COPD severity and outcome.

Serum HA was assessed in a discovery cohort of 80 COPD patients at stable state and exacerbations. HA, HYAL-1 and HYAL-1 enzymatic activity were evaluated at stable state, exacerbations and 4 weeks after exacerbations in 638 COPD patients from the PROMISE validation cohort.

In the discovery cohort, serum HA was higher at exacerbations compared with the stable state (p=0.015). In the validation cohort, HA was higher at moderate and severe exacerbations than at baseline (p

Serum HA is associated with COPD severity and predicts overall survival. Degradation of HA is associated with airflow limitation and impairment of lung function.

Original language	English
Article number	1801183
Number of pages	13
Journal	European Respiratory Journal
Volume	53
Issue number	3
DOIs	https://doi.org/10.1183/13993003.01183-2018
Publication status	Published - 1 Mar 2019

Keywords

ANGIOGENIC OLIGOSACCHARIDES
LUNG
EXACERBATIONS
BIOMARKERS
MORTALITY
FRAGMENTS
ADRENOMEDULLIN
METABOLISM
EXPRESSION
DEPOSITION

Access to Document

10.1183/13993003.01183-2018

Cite this

Papakonstantinou, E., Bonovolias, I., Roth, M., Tamm, M., Schumann, D., Baty, F., Louis, R., Milenkovic, B., Boersma, W., Stieltjes, B., Kostikas, K., Blasi, F., Aerts, J. G., Rohde, G. G. U., Lacoma, A., Torres, A., Welte, T., & Stolz, D. (2019). Serum levels of hyaluronic acid are associated with COPD severity and predict survival. European Respiratory Journal, 53(3), Article 1801183. https://doi.org/10.1183/13993003.01183-2018

@article{e1f26e5097984aa5b046376678eda5c5,

title = "Serum levels of hyaluronic acid are associated with COPD severity and predict survival",

abstract = "Hyaluronic acid (HA) and its degradation products play an important role in lung pathophysiology and airway remodelling in chronic obstructive pulmonary disease (COPD).We investigated if HA and its degrading enzyme hyaluronidase (HYAL)-1 are associated with COPD severity and outcome.Serum HA was assessed in a discovery cohort of 80 COPD patients at stable state and exacerbations. HA, HYAL-1 and HYAL-1 enzymatic activity were evaluated at stable state, exacerbations and 4 weeks after exacerbations in 638 COPD patients from the PROMISE validation cohort.In the discovery cohort, serum HA was higher at exacerbations compared with the stable state (p=0.015). In the validation cohort, HA was higher at moderate and severe exacerbations than at baseline (pSerum HA is associated with COPD severity and predicts overall survival. Degradation of HA is associated with airflow limitation and impairment of lung function.",

keywords = "ANGIOGENIC OLIGOSACCHARIDES, LUNG, EXACERBATIONS, BIOMARKERS, MORTALITY, FRAGMENTS, ADRENOMEDULLIN, METABOLISM, EXPRESSION, DEPOSITION",

author = "Eleni Papakonstantinou and Ioannis Bonovolias and Michael Roth and Michael Tamm and Desiree Schumann and Florent Baty and Renaud Louis and Branislava Milenkovic and Wim Boersma and Bram Stieltjes and Konstantinos Kostikas and Francesco Blasi and Aerts, {Joachim G.} and Rohde, {Gernot G. U.} and Alicia Lacoma and Antoni Torres and Tobias Welte and Daiana Stolz",

note = "Funding Information: Support statement: This study was funded by Schweizerischer Nationalfonds zur F{\"o}rderung der Wissenschaftlichen Forschung (PP00-P3_128412/1), Swiss Lungenliga (2015-18) and Universit{\"a}t Basel (DMS 2182). Funding information for this article has been deposited with the Crossref Funder Registry. Publisher Copyright: Copyright {\textcopyright}ERS 2019",

year = "2019",

month = mar,

day = "1",

doi = "10.1183/13993003.01183-2018",

language = "English",

volume = "53",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "3",

}

Papakonstantinou, E, Bonovolias, I, Roth, M, Tamm, M, Schumann, D, Baty, F, Louis, R, Milenkovic, B, Boersma, W, Stieltjes, B, Kostikas, K, Blasi, F, Aerts, JG, Rohde, GGU, Lacoma, A, Torres, A, Welte, T & Stolz, D 2019, 'Serum levels of hyaluronic acid are associated with COPD severity and predict survival', European Respiratory Journal, vol. 53, no. 3, 1801183. https://doi.org/10.1183/13993003.01183-2018

TY - JOUR

T1 - Serum levels of hyaluronic acid are associated with COPD severity and predict survival

AU - Papakonstantinou, Eleni

AU - Bonovolias, Ioannis

AU - Roth, Michael

AU - Tamm, Michael

AU - Schumann, Desiree

AU - Baty, Florent

AU - Louis, Renaud

AU - Milenkovic, Branislava

AU - Boersma, Wim

AU - Stieltjes, Bram

AU - Kostikas, Konstantinos

AU - Blasi, Francesco

AU - Aerts, Joachim G.

AU - Rohde, Gernot G. U.

AU - Lacoma, Alicia

AU - Torres, Antoni

AU - Welte, Tobias

AU - Stolz, Daiana

N1 - Funding Information: Support statement: This study was funded by Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00-P3_128412/1), Swiss Lungenliga (2015-18) and Universität Basel (DMS 2182). Funding information for this article has been deposited with the Crossref Funder Registry. Publisher Copyright: Copyright ©ERS 2019

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Hyaluronic acid (HA) and its degradation products play an important role in lung pathophysiology and airway remodelling in chronic obstructive pulmonary disease (COPD).We investigated if HA and its degrading enzyme hyaluronidase (HYAL)-1 are associated with COPD severity and outcome.Serum HA was assessed in a discovery cohort of 80 COPD patients at stable state and exacerbations. HA, HYAL-1 and HYAL-1 enzymatic activity were evaluated at stable state, exacerbations and 4 weeks after exacerbations in 638 COPD patients from the PROMISE validation cohort.In the discovery cohort, serum HA was higher at exacerbations compared with the stable state (p=0.015). In the validation cohort, HA was higher at moderate and severe exacerbations than at baseline (pSerum HA is associated with COPD severity and predicts overall survival. Degradation of HA is associated with airflow limitation and impairment of lung function.

AB - Hyaluronic acid (HA) and its degradation products play an important role in lung pathophysiology and airway remodelling in chronic obstructive pulmonary disease (COPD).We investigated if HA and its degrading enzyme hyaluronidase (HYAL)-1 are associated with COPD severity and outcome.Serum HA was assessed in a discovery cohort of 80 COPD patients at stable state and exacerbations. HA, HYAL-1 and HYAL-1 enzymatic activity were evaluated at stable state, exacerbations and 4 weeks after exacerbations in 638 COPD patients from the PROMISE validation cohort.In the discovery cohort, serum HA was higher at exacerbations compared with the stable state (p=0.015). In the validation cohort, HA was higher at moderate and severe exacerbations than at baseline (pSerum HA is associated with COPD severity and predicts overall survival. Degradation of HA is associated with airflow limitation and impairment of lung function.

KW - ANGIOGENIC OLIGOSACCHARIDES

KW - LUNG

KW - EXACERBATIONS

KW - BIOMARKERS

KW - MORTALITY

KW - FRAGMENTS

KW - ADRENOMEDULLIN

KW - METABOLISM

KW - EXPRESSION

KW - DEPOSITION

U2 - 10.1183/13993003.01183-2018

DO - 10.1183/13993003.01183-2018

M3 - Article

C2 - 30705130

SN - 0903-1936

VL - 53

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 3

M1 - 1801183

ER -